Aurinia Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary

Aurinia Pharmaceuticals

02/05/2024 20:48

* Aurinia Pharmaceuticals Inc  AUPH.OQ  reported a quarterly
adjusted loss of 3 cents​​ per share for the quarter ended in
March, higher than the same quarter last year, when the company
reported EPS of -18 cents.  The mean expectation of six analysts
for the quarter was for a loss of 14 cents per share. Wall
Street expected results to range from -20 cents to 1 cents per
share.
    * Revenue rose 46.2% to $50.30 million from a year ago;
analysts
expected $47.45 million. 
    * Aurinia Pharmaceuticals Inc's reported EPS for the quarter
was a
loss of 7 cents​.
    * The company reported a quarterly loss of $10.75 million.
    * Aurinia Pharmaceuticals Inc shares had risen by 3.8% this
quarter and lost 42.2% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had fallen by
about 1.2%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 
    * Wall Street's median 12-month price target for Aurinia
Pharmaceuticals Inc is $11.00 

This summary was machine generated from LSEG data May 2 at 07:48
p.m. UTC. ​All figures in US dollars unless otherwise stated.
(For questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2024      -0.14          -0.03          Beat
 Dec. 31 2023      -0.16          -0.19          Missed
 Sep. 30 2023      -0.17          -0.09          Beat
 Jun. 30 2023      -0.18          -0.08          Beat